Comparing the current results to its competitors, Zai Lab Limited reported Revenue decrease in the 1 quarter 2026 year on year by -6.46 %, despite the revenue increase by the most of its competitors of 36.44 %, recorded in the same quarter.
Zai Lab Limited's Comment on Competition and Industry Peers
The biopharmaceutical industry is characterized by intense competition among biotechnology and pharmaceutical companies developing products for similar approved indications and therapeutic areas. Competitors often possess significantly greater financial, marketing, research and development resources. Success in this industry relies on managerial and technological expertise, innovation, established patent and proprietary rights, and the ability to secure product approval, acceptance, and utilization. Additional competitive factors include patent status, product efficacy and safety, patient convenience, delivery mechanisms, reliability, availability, reimbursement, pricing, and the speed of product development and market introduction. The launch of new products or technologies by competitors can increase competition and pricing pressures, potentially diminishing the use or effectiveness of existing products and clinical trials.
September 6, 2025
In recent developments within the biotechnology sector, Zai Lab Limited (NASDAQ: ZLAB) has emerged as a focal point for both investor scrutiny and competitive analysis. The Pomerantz Law Firm has initiated an investigation into the nebulous circumstances surrounding Zai Lab’s financial performance, particularly as its results have drawn attention amidst increased competition. This article delves into the company’s recent revenue reports in the second quarter of 2025, a comparative analysis with its competitors, and implications for current and prospective investors. Investor Alert: Legal Investigations on Zai Lab Limited On September 6, 2025, the Pomerantz Law Firm announced an investigation into claims ...
April 21, 2025
In a recent press release, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) made a significant announcement regarding the acceptance of its supplemental New Drug Application (sNDA) for repotrectinib by China s National Medical Products Administration (NMPA). This application targets adult patients with solid tumors that harbor neurotrophic tyrosine receptor kinase (NTRK) gene fusions, specifically for those with locally advanced or metastatic diseases where surgery is not a viable option. Repotrectinib, an investigational compound, has demonstrated a strong potential in targeting tumors characterized by NTRK gene fusions, which are critical drivers in various cancers. The acceptance of this sNDA encourages signifi...
November 28, 2024
In a significant advancement for both healthcare access and cancer treatment in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced the inclusion of AUGTYRO (repotrectinib) in the recently updated National Reimbursement Drug List (NRDL). The announcement, made in Shanghai and Cambridge, marks a crucial step in improving treatment options for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). This inclusion, released by China’s National Healthcare Security Administration (NHSA), highlights the company’s commitment to providing innovative therapies that meet the pressing healthcare needs of the population.AUGTYRO is a targeted therapy specifically d...
November 15, 2024
Zai Lab Limited Prices Public Offering Amidst Strong Revenue Growth and Competitive LandscapeIn a significant move to bolster its financial standing, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a leading biopharmaceutical company based in Shanghai and Cambridge, has announced the pricing of its underwritten public offering of American depositary shares (ADSs). The offering consists of 7,843,137 ADSs, with each ADS representing ten ordinary shares of the Company, priced at US$25.50 per share. This capital raise is expected to yield gross proceeds of approximately $200 million before the deduction of underwriting discounts, commissions, and other associated costs.As Zai Lab progresses through the second quart...
May 20, 2024
Zai Lab and Innoviva Specialty Therapeutics Gain NMPA Approval for New Drug XACDURO for Treating Serious Pneumonia in ChinaSHANGHAI and CAMBRIDGE, Mass. and WALTHAM, Mass. - Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Innoviva Specialty Therapeutics have announced that China s National Medical Products Administration (NMPA) has granted approval for Zai Lab s New Drug Application (NDA) for XACDURO (sulbactam-durlobactam) for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.Hospital-acquired and ventilator-associated pneumonia are serious and potentially life-thre...
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Aclaris Therapeutics Inc is a company that focuses on developing and commercializing innovative therapies to address significant unmet needs in dermatology and immunology. Their business model involves researching and developing treatments for various skin and hair conditions, obtaining regulatory approvals, and marketing these therapies to healthcare professionals and patients.
Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.
Allakos Inc's business model revolves around developing and commercializing innovative therapeutic antibodies to treat allergic and inflammatory diseases.
Sources:
Zai Lab Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zai Lab Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
